Showing 227 results

Filters Content type: News, Editors' picks Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

Injectable & long-acting HIV treatment

Failed viral suppression in CAB/RPV linked to 3 Risk Factors

Editor's pick
Medscape (requires free registration)
28 July 2021
Improving HIV care

Long-acting injectable HIV treatment is feasible, even during COVID-19

News
20 July 2021
Injectable & long-acting HIV treatment

Twice-a-year injected drug shows promise for first-line HIV treatment

News
19 July 2021
New & experimental HIV treatments

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy

News
17 July 2021
Pharmaceutical industry

GSK puts long-acting injectables at heart of HIV growth plans, downplays threat of oral rival from Gilead and Merck

Editor's pick
FiercePharma
29 June 2021
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Editor's pick
Gilead press release
29 June 2021
Injectable & long-acting HIV treatment

GSK's ViiV, under threat from Gilead-Merck collab, eyes 'ultra-long-acting' HIV drugs with Halozyme deal

Editor's pick
FiercePharma
23 June 2021
Injectable & long-acting HIV treatment

Long-acting Injectables: when will they be available in the UK?

Editor's pick
UK-CAB
21 June 2021
Resistance

Injectable HIV therapy should only be given after a check for innate resistance, French study suggests

News
8 June 2021
Injectable & long-acting HIV treatment

Long-Acting ART Rollout: 3 Considerations for Clinicians

Editor's pick
TheBodyPro
26 May 2021
Injectable & long-acting HIV treatment

GlaxoSmithKline's ViiV preps doctors ahead of Cabenuva's patient marketing push

Editor's pick
FiercePharma
26 May 2021
Injectable & long-acting HIV treatment

Enthusiasm for Once-Monthly Cabenuva Is High—But There Are Questions, Too

Editor's pick
TheBody
18 May 2021
Injectable & long-acting HIV treatment

Injectable HIV therapy would have to cost less than $131 a year to be cost-effective in Africa

News
16 April 2021
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and prevention from CROI 2021

News
23 March 2021
Injectable & long-acting HIV treatment

Injectable HIV medications must be practical and affordable, conference hears

News
15 March 2021
Injectable & long-acting HIV treatment

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Editor's pick
Gilead press release
15 March 2021
Injectable & long-acting HIV treatment

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years

News
12 March 2021
TB treatment

Should TB Treatment Move into Long-Acting Injectables?

Editor's pick
Contagion Live
11 March 2021
New & experimental HIV treatments

HIV capsid inhibitor offers new option for people with highly resistant HIV

News
10 March 2021
Injectable & long-acting HIV treatment

ViiV Seeks FDA Approval for Cabenuva Dosed Every 2 Months for HIV

Editor's pick
Monthly Prescribing Reference
26 February 2021
Injectable & long-acting HIV treatment

Cabenuva, the First Long-Acting Injectable HIV Regimen, Is Here; Now, Who Will Take It?

Editor's pick
TheBody
29 January 2021
Injectable & long-acting HIV treatment

Previous Intravenous Drug Use May Impact Women's Comfort With Injectable HIV Medications

Editor's pick
American Journal of Managed Care
25 January 2021
Injectable & long-acting HIV treatment

FDA approves first long-acting injectable to treat HIV infection

Editor's pick
STAT
22 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Editor's pick
ViiV Healthcare press release
22 January 2021